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ABSTRACT
Hogg, Brendan, M.S., Spring 2018

Health and Human Performance

Interleukin-6, a novel myokine
Chairperson: John C. Quindry, PhD
Interleukin-6 (IL-6) was first identified as a pleiotropic cytokine, with a host of body-wide
functions. Cytokine functions are characterized by chronically elevated levels within various
inflammatory states. In this regard, IL-6 is largely associated with the acute phase response to
many stimuli and performs specific actions when produced from certain cell types. Accrued
evidence indicates IL-6 release from skeletal muscle often includes myokine functions. Novel
myokine functions are adaptive in nature, and as compared to inflammatory/cytokine roles, exhibit
a transient time course. Following exercise plasma IL-6 peaks and returns to resting levels within
1-2 hours. In contrast, IL-6 is observed to be consistently elevated in a much longer time course
during inflammatory disease states. Production and release of IL-6 is reliant on many stress
dependent factors, but from a skeletal muscle perspective, the release appears to be
bioenergetic/fatigue dependent. Moreover, long duration in conjunction with high intensity
exercise results in the greatest IL-6 production. Association between IL-6 and the metabolic status
of skeletal muscle, in regards to glycogen content and glucose uptake, has provided a new avenue
of research. The acute increase in circulating IL-6 following exercise indicates divergent roles for
IL-6. Recent evidence indicates that IL-6 exerts regulatory cyto-protection in regards to insulin
sensitivity and metabolic stress. In addition, recent data suggest that IL-6 is central within
mechanisms regarding cardio-protection from ischemic injury. Given these widespread benefits,
there is reason to suspect additional myokine roles of IL-6 are on the horizon. Further research
efforts with mechanistic approaches should be directed toward investigating skeletal muscle
derived IL-6 in regards to exercise-induced protection from metabolic and ischemic injury.
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Interleukin-6 (IL-6): Cytokine Vs Myokine
Over the last decade investigations designed to target interleukin-6 (IL-6) provide new
understanding of health and disease progression. Overarching conclusions reveal that interleukin6 is largely associated with inflammatory and auto-immune processes observed in various diseases
such as diabetes, atherosclerosis, systemic lupus erythematosus and rheumatoid arthritis
(Kristiansen & Mandrup-Poulsen, 2005; Dubiński, et al., 2007; Tackey et al., 2004; Nishimoto, et
al., 2006). Moreover, mechanistic studies report that IL-6 overexpression leads to systemic
inflammation, altered metabolic function as well as severe liver inflammation (Franckhauser, et
al., 2008). IL-6 is not exclusively observed in detrimental disease states as evidenced by its acute
appearance in circulation during and following exercise. Furthermore, ample evidence exists
indicating that IL-6 possesses anti-inflammatory and even cyto-protective properties (Pedersen,
2017). IL-6 communicates with various cell types, in turn exerting systemic effects, which
highlight a far-reaching influence within human biology (Kishimoto, 1992). The initially
perplexing and pleiotropic characteristics of IL-6 have recently been revealed within the context
of health and disease.
Cytokine research provides a better understanding of homeostatic function and disease
progression. Cytokines are signaling proteins produced from a variety of immune cells and act in
paracrine, autocrine and endocrine manners influencing the adaptive and innate immune systems
(Kian Fan Chung, 2009). IL-6 is one of the most extensively documented cytokines, with attention
being justified due to its ubiquitous nature and chronic elevation within various inflammatory
disease states. Interleukin-6 was first identified in 1980 after researchers aimed to clone the
interferon (IFN)-β gene within human fibroblasts (Weissenbach, et al., 1980; Van Snick, et al.,
1990). However, it was not until 1989 that researchers came to agreement and labeled the
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mysterious protein “interleukin-6” (Akira, et al., 1993). Early evidence suggested appearance of
IL-6 in circulation was mainly the result of stimulated immune cells such as macrophages,
fibroblasts, as well as T-cells, B-cells, and white blood cells (Andus, et al., 1998; Akira, et al.,
1993). IL-6 production from immune cells and subsequent action is influenced by the presence of
other pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1β
(IL-1β). Ample evidence supports a cytokine role of IL-6 in the host defense mechanism/acute
phase response to trauma, burns and infection; hematopoiesis and stimulating the synthesis and
release of acute phase proteins and antibodies (Andus, et al., 1988; Tanaka, Narazaki and
Kishimoto, 2014). Due to the association between IL-6 and inflammatory states, it is
understandable that early published findings promoted the notion that plasma IL-6 elevations in
response to exercise were a result of tissue damage and inflammatory processes.
IL-6 release following exercise is not dependent on muscle damage. Initial findings of
increased circulating IL-6 concentrations post-exercise were first observed by Northoff & Berg in
1991. In the context of the conventional understanding of IL-6 as an important moderator in
immune cell function and proliferation, the increase in IL-6 post-exercise was thought to be due
to immune cell recruitment following muscle damage. Bruunsgaard et al., (1997) observed larger
and prolonged circulating IL-6 concentrations following muscle damaging-eccentric exercise
compared to that of concentric exercise (30 min at >100 % VO2max vs. 65 % VO2max,
respectively). In their now classic work, this team of researchers suggested that peak IL-6
concentrations following eccentric modalities were associated with elevated creatine kinase (CK)
levels following exercise, depicting a possible dependency on muscle damage (Bruunsgaard, et
al., 1997). The early assumptions that tissue damage serves as a prime initiator have now been
rebutted by multiple groups of investigators that observed a much more prominent peak in IL-6
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concentration following concentric exercise compared to previously executed eccentric models
(~100-fold vs. ~5-fold) (Ostrowski et al., 1999). Ostrowkski, et al., (1999) observed peak CK
levels 24 hours post concentric exercise with no relationship between peak IL-6 levels and peak
CK levels (Ostrowski et al., 1999). Additionally, it is well established that adhesion molecules
following muscle damage attract leukocytes to the inflamed location and IL-6 when acting as a
cytokine signaler from immune cells stimulates the binding of adhesion molecules to leukocyte
and endothelial cells (Akimoto, et al., 2002; Chen et al., 2006, Kaplanski, et al., 2003). Yet,
published findings from multiple research teams report unaltered expression of adhesion molecules
following exercise despite an exercise induced IL-6 increase, indicating two things: 1) IL-6
production occurs independent of muscle damage and 2) IL-6 production during/following
exercise exhibits an alternate function than that of traditional cytokine processes (Smith et al.,
2000, Chaar, et al., 2011). Accordingly, the more novel idea of circulating IL-6 post-exercise, does
not negate the well-established fact that muscle damaging eccentric exercise likely initiates more
traditional cytokine actions of IL-6 from immune cells. As such, dynamic exercise with a
concentric emphasis provides muscle-derived IL-6 release into circulation; a response that appears
to be largely independent of inflammation.
IL-6 is expressed, produced and released from skeletal muscle. Ostrowski, et al., (1998b)
as well as Steensberg et al. (2000) were frontrunners in identifying IL-6 release directly from
skeletal muscle in response to exercise. More recent research indicates vesicles at the sarcolemma
and T-tubule that contain IL-6 protein, which upon muscular contraction decrease in content
(Lauritzen, et al., 2013). Bente Pedersen and colleagues (2003) were an innovative team of
researchers who coined the term “myokine.” A myokine is described as a hormone-like protein
produced, expressed and released from skeletal muscle tissue (Pedersen et al., 2003). Similar to
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cytokine function, IL-6 is currently the most thoroughly studied myokine. Early attention given to
IL-6 is appropriate in that a post-exercise spike in circulating IL-6 precedes the appearance of other
myokines. To this end, IL-6 appears in circulation within 10 min of exercise (Macdonald, et al.,
2003, Nieman, et al., 2007). Unlike its cytokine functions, the time course of skeletal muscle
derived IL-6 release and disappearance in circulation is transient, with levels returning to baseline
within two hours post-exercise. Furthermore, production via skeletal muscle fibers during exercise
does not activate pro-inflammatory pathways (Pedersen & Febbraio, 2008). For example,
monocytes produce and initiate the cytokine role of IL-6 during sepsis, yet monocytes do not
express an increase in IL-6 protein during exercise (Moldoveanu, et al., 2000; Starkie, et al., 2001).
IL-6 is produced from all fiber types of skeletal muscle, but IL-6 mRNA concentrations following
exercise increase predominately in type II muscle fibers, which also contain higher glycogen
content. While this is not fully understood, early scientific speculation demonstrates that type II
fibers are central to the production of IL-6 during muscular contraction (Hiscock, et al., 2004).
Supporting this tentative conclusion, McGinnis et al., (2015) observed in exercised muscle that
fiber type specific IL-6 mRNA expression occurs. Tentative findings are supported by findings
from real-time PCR (polymerase chain reaction) performed in skeletal muscles of the lower limb.
Specifically, cardiomyocytes had the lowest expression while extensor digitorum longus (largely
type II) contained the largest expression. With higher expression in type II fibers, it is clear that
IL-6 release from skeletal muscle is influenced by exercise intensity due to type II (glycolytic)
skeletal muscle fibers being highly recruited with increased exercise intensity (Yamano, et al.,
2010).
Cell signaling is heavily influenced by cytokines in a vast range of bodily processes. Over
expression of certain cytokines occurs in numerous disease states, highlighting the importance of
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investigating the regulatory processes in which these substances are involved. Cytokine secretion
is not limited to immune cells, as seen by IL-6 production from skeletal muscle during and
following exercise. A body of published data underpins a growing consensus that skeletal muscle
acts in endocrine fashion, highlighting the prospect of distinct IL-6 signaling pathways involved
with organ cross-talk (Pedersen & Febbraio, 2008). Collectively, a wealth of knowledge
surrounding exercise and IL-6 signaling depicts specific responses to other cytokines, exercise
duration, exercise intensity, as well as glucose and glycogen availability.

Relationship between circulating TNF-α and IL-6
The action of circulating IL-6 is altered when in the presence of TNF-α. TNF-α is a
multifaceted inflammatory cytokine produced predominantly by macrophages, natural killer cells
and lymphocytes (Clyde & Glaunsigner, 2010). Antagonists of TNF-α are effectively utilized to
treat inflammatory disorders such psoriasis, rheumatoid arthritis and inflammatory bowel disease
(Esposito, & Cuzzocrea, 2009). During severe infections (i.e. sepsis) and cardiometabolic disease,
chronically elevated plasma concentrations of TNF-α and IL-6 are consistently observed
(Pedersen, 2017). Upon stimulation, in scenarios such as sepsis, macrophages secrete a
combination of pro-inflammatory cytokines: TNF-α, IL-1β and IL-6. Compared to sepsis, exercise
results in different cytokine responses: transient increases of IL-6 with no acute increases in TNFα nor IL-1β. Rather, skeletal muscle derived IL-6 has downstream anti-inflammatory effects such
as inhibition of TNF-α and stimulation of cortisol and anti-inflammatory cytokines IL-10 and IL1ra (interleukin-1 receptor antagonist) (Steensberg, et al., 2003). TNF-α is a potent inflammatory
cytokine, and acts in union with IL-6 during inflammation (Pedersen, 2017). IL-6, unaccompanied
by TNF-α, exhibits different and even anti-inflammatory effects.
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IL-6 in response to exercise provides an anti-inflammatory environment by suppressing
TNF-α. For instance, Starkie, et al., (2003) identified direct inhibition of TNF- α following exercise
and recombinant IL-6 infusion. Researchers induced a low grade inflammatory state by
administering E. coli to healthy subjects following 3h rest, 3h cycling or 3h infusion of
recombinant IL-6. The intravenous bolus of E. coli resulted in a two- to three-fold increase in TNFα while subjects were at rest, however following exercise TNF-α was completely blunted. The
exercise induced blunting effect of exercise was nearly identical to exercise independent IL-6
infusion (eliciting same concentration as stimulated by exercise). These findings support the notion
that IL-6 myokine action attenuates the appearance of TNF-α and may serve as a cytoprotective
mechanism. In regards to metabolic function, TNF-α induces peripheral insulin resistance whereas
recent findings indicate that IL-6 protects against metabolic damage and improves glucose
tolerance (Plomgaard, et al., 2005; Carey, et al., 2006; Ellinsgaard, et al., 2008). IL-6 is no longer
regarded as solely a synergist to TNF-α, with evidence indicating counter regulatory effects. In
scenarios when TNF-α is not present, such as exercise, IL-6 undergoes phenomenological
differences in magnitude, time and action than its customary cytokine roles (Reihmane et al., 2012;
Steensberg, et al., 2002; Ostrowski, et al., 1998b).

Tissue specificity and IL-6 signaling
Actions of IL-6 are dependent on the source of production/release. Cytokine and myokine
properties of IL-6 are clearly differentiated by their unique upstream and downstream signaling
cascades as seen by the altered pathways in skeletal muscle and immune cell (macrophages) IL-6
secretion (Fig. 1). Stimulation of nuclear factor-kappaB (NF-kappaB) due to the activation of the
TLR (toll like receptor) signaling cascade results in TNF-α, IL-1β and IL-6 release from
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macrophages in scenarios such as sepsis. When produced in union with one another TNF-α, IL-1β
and IL-6 act in synergy. However, upon muscular contraction IL-6 is not dependent on this
stimulatory profile. Rather, the exclusive release of IL-6 from myocytes is suggested to be due to
transcriptional control mediated by nitric oxide (NO) (Steensberg, et al., 2007). Steensberg, et al.
(2007) observed that inhibiting NO production during exercise attenuated IL-6 protein release.
Further downstream pathways involve a distinguishing network of cellular interactions involving
nuclear factor of activated T cells (NFAT) and/or p38 mitogen activated protein kinase (p38MAPK). Moreover, during exercise the sarcoplasmic reticulum releases calcium (Ca2+) resulting
in muscular contractions. Lower intracellular concentrations of Ca2+, as seen during prolonged
exercise, activates NFAT through the action of calcineurin (Im & Rao, 2004). NFAT expression
is substantially higher in skeletal muscle compared to other cell types and NFAT has been shown
to increase IL-6 mRNA expression within human muscle cells (Keller, et al., 2006). In addition to
the sustained fatiguing mechanism of lowered Ca2+ during long durations, decreased fuel reserves
(i.e. glycogen) is important. Prolonged exercise decreases muscle glycogen content, which in turn
increases the phosphorylation of p38 MAPK within nuclei (Chan, et al., 2004). To this end,
inhibition of p38 MAPK phosphorylation decreases IL-6 mRNA expression in muscle tissue
(Chan, et al., 2004). Fatigue processes associated with exercise appears to be a potent stimulus of
IL-6 production from skeletal muscle. In addition to source of production and receptor type, the
unique myokine production pathways of IL-6 further highlight the difference between traditional
cytokine processes.
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Figure 1. Differences between macrophage and skeletal muscle stimulation of IL-6 release into circulation. Adapted
from Pedersen & Febbraio, 2008.

IL-6 production from various cell types initiates subsequent action on target tissues via
unique receptor complexes. Receptor complexes, source of production as well as upstream and
downstream signaling pathways influence IL-6 action. IL-6 has two receptor-mediated signaling
approaches, referred to as classic signaling and trans-signaling (Fig. 2). In classic signaling,
activity of IL-6 is mediated via two membrane bound proteins; the ligand-binding receptor (IL6R) and the signal transducing glycoprotein-130 (gp130) (Kishimoto, 1992). All mammalian cells
display the gp130 on their cell membranes, thereby eliciting downstream effects on various cell
types (Scheller, et al., 2011). However, not all cells express the membrane bound IL-6R, thus the
importance of having another signaling mechanism, trans-signaling. Components of this alternate
pathway comprise of an extracellular soluble IL-6 receptor (sIL-6R) formed primarily via
proteolytic shedding of the membrane bound IL-6R (Scheller, et al., 2011). Whether classical or
trans-signaling occurs, the complex of the receptor and gp130 leads to the signal transduction of
IL-6 which then activates the pathways: JAK/STAT (janus kinase/signal transducer and activator
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of transcription), ERK (extracellular signal-regulated kinase), and PI-3K (phosphoinositide 3kinase).

Figure 2. IL-6 classical and trans-signaling. Proteolytic shedding of the membrane bound receptor results in a soluble
IL-6 receptor that then binds to gp130 and produces signal transduction of JAK/STAT, ERK, PI-3K pathways which
activate transcription factors. Adapted from Reihmane & Dela, 2014.

Recently published preliminary evidence suggests that IL-6 activates different upstream
and down-stream signaling pathways leading to specific cellular interactions, clarifying the
discrepancy between cytokine and myokine functions. Skeletal muscle derived IL-6 signals the
myocardium post-exercise through alternate pathways compared to cytokine signaling.
Downstream of the IL-6R/gp130 complex, IL-6 signaling pathways are different when IL-6 is
secreted as a cytokine versus a myokine (Fig. 3). During ischemic preconditioning (IPC) trials, IL6 acts through the JAK/STAT and PI-3K pathways initiating protection from ischemic reperfusion
injury (I/R) by activating downstream IPC mediators iNOS (inducible nitric oxide synthase) and
COX-2 (cyclooxygenase-2). McGinnis, et al. (2015) observed that following exercise
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preconditioning and subsequent I/R, IL-6 did provide protection from myocardial necrosis,
however not through traditional cytokine signaling. Following exercise, investigators observed
that JAK/STAT and PI-3K pathways did not initiate the protective effects (downstream activation
of COX-2 and iNOS) of IL-6 signaling within the heart. Based on these findings, one might infer
that exercise induced release of IL-6 follows an alternative route by which the myokine IL-6
initiates transcription. Further discussion of these novel findings will be provided in a later section
(Cardioprotection), due to the ground breaking notion that skeletal muscle derived IL-6 exhibits
endocrine properties albeit through unidentified signaling pathways. In addition to the apparent
differences in myokine and cytokine signaling within the myocardium, secretory pathways of IL6 change from immune cells to myocytes.

Figure 3. Cytokine signaling compared with myokine signaling as proposed by McGinnis et al., (2015).

As a generalization, the sIL-6R is associated with undesirable processes while the
membrane bound IL-6R is more often associated with beneficial effects on homeostasis. For
instance, pro-inflammatory effects of IL-6 are mostly mediated by trans-signaling (Kraakmen et
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al., 2013; Rose-John, et al., 2007, Kraakmen et al, 2015). Early conclusions are supported by the
observation that blockage of IL-6 trans-signaling in mice resulted in decreased inflammation in
atherosclerosis (Scheutt, et al., 2012). Furthermore, use of tissue-specific deletion of membrane
bound IL-6R (classical signaling) in murine hepatocytes, mice demonstrated detrimental
metabolic phenotypes in regards to insulin resistance and glucose intolerance and liver
inflammation (Wunderlich et al., 2010; Mauer et al., 2014). However, caution is warranted from
broad based conclusions since the respective roles of membrane bound and soluble IL-6 receptor
activation are still being defined in the context of myokine stimuli. Case in point, in addition to
increasing circulating IL-6 protein, exercise also increases both membrane bound IL-6R and the
sIL-6R in plasma and skeletal muscle (Leggate, et al., 2010; McGinnis, et al., 2015). The
production of this myokine is heavily influenced by fatigue mechanisms, which are stimulated by
higher intensity and longer duration exercise. The phenomenological differences between IL-6
cytokine and myokine signaling have yet to be completely resolved. However, the upstream and
downstream signaling pathways accompanied by the alternate receptor complexes provide a solid
foundation in identifying fundamental differences between cytokine and myokine actions.

Role of exercise intensity and duration on IL-6 production
The magnitude in the spike of circulating IL-6 during and post-exercise appears to be
influenced by the amount of muscle mass recruited. Running, which recruits a large amount of
muscle mass by virtue of lower and upper body movement, typically results in the largest
circulating spike in post-exercise IL-6 (Nieman et al., 1998, Starkie, et al., 2000, 2001, Ostrowski,
1998b). In agreement, exercise limited to the upper extremities does not produce a dramatic IL-6
elevation post-exercise (Bergfors, et al., 2005; Hirose, et al., 2004). Although the amount of
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contracting skeletal muscle influences IL-6 magnitude within circulation, the intensity and
duration of exercise are the most potent stimulators of IL-6 production, independent of modality.
With higher intensity and longer duration, human skeletal muscle performance is hindered by
inevitable fatigue. As noted earlier, muscular fatigue is a powerful promoter of IL-6 release from
skeletal muscle.

Intensity
Elevated levels of IL-6 are consistently observed following strenuous exercise indicating
the influence of exercise intensity on IL-6 production. For instance, early published findings
indicate a two-fold increase in plasma IL-6 following 6 min of “all out” rowing at a workload of
400 watts (Nielsen, et al., 1996). Similar findings of a mild increase were observed following 2
hours of whole body resistance training consisting of four sets of ten repetitions at 40-60% 1RM
(1 set at 40% and 3 at 60% 1RM). A six-fold increase in plasma IL-6 from pre to post-exercise
was observed (Nieman, et al., 2003). Later investigations revealed that IL-6 release is directly
influenced by exercise intensity (Helge et al., 2003; Ostrowski et al., 2000). Helge et al. (2003)
reported that plasma IL-6 concentrations increased proportionally to exercise intensity with a main
effect of p < 0.05. Subjects performed double knee extension for 45 min at 25% Wmax followed by
an additional 35 min where one leg exercised at 65% Wmax and the other at 85% Wmax. Using the
Fick principle (femoral arterial-venous difference X blood flow) researchers identified differences
in IL-6 release between both legs. The highest IL-6 release was observed at 85% Wmax, eliciting
nearly a six-fold increase from resting values (p <0.05), whereas release at 65% and 25% Wmax did
not exceed a three-fold increase. Notably, at both intensities (65% and 85% Wmax) IL-6 release
increased over time, suggesting a positive associative relationship with exercise duration.
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Duration
The majority of plasma IL-6 elevations following exercise is attributed to exercise duration
(Fischer, 2006). Rest intervals do not significantly affect IL-6 production as seen by Nieman et al.
(2007). Nieman, et al., reported a 40-fold increase in plasma IL-6 concentrations in both
continuous and intermittent exercise groups where individuals cycled for 2 hours at an intensity of
75% VO2max. Comparatively, a mere five-fold increase in arterial IL-6 concentrations was
observed after cycling for 1 hour at a similar intensity; 70% VO2max (p < 0.05) (Macdonald, et
al., 2003). Ostrowski et al. (1998a) observed during treadmill running at 75% VO2max that
circulating IL-6 levels were elevated 30 min into the bout (four-fold increase from rest) but peaked
at 2.5 hr of exercise (25-fold from rest), supplying further evidence that increases in plasma IL-6
during exercise are largely affected by duration. Ostrowski and colleagues continued their
investigation, by observing IL-6 response following a marathon, where IL-6 levels increased
markedly following the race (completion time: 3hr 17min ± 7.39 min) (Ostrowski, et al., 1998b).
IL-6 plasma concentrations collected immediately post-race, revealed a near 100-fold increase
from 1.5 ± 0.7 at rest to 94.4 ± 12.6 pg/ml. In the same study a significant decline in IL-6 plasma
concentration was observed 2 hour post-exercise, resulting in 22.1 ± 3.8 pg/ml, elucidating the
transient response to exercise. Another group of researchers observed similar findings of a 100fold increase in plasma IL-6 post marathon, (mean finish time = 2hr 37min) (Suzuki, et al., 2003).
Contrarily, other teams of investigators failed to report the same magnitude of IL-6 appearance
following marathon running (Bernecker, et al., 2013; Nieman, et al., 2001). The large disparity
among finish times between the two sets of studies (1-1.5 hr) may be the mitigating factor behind
the different amplitudes of circulating IL-6, although sample collection and handling are also likely
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explanations. Nonetheless, IL-6 secretion from skeletal muscle is heavily influenced by the length
of exercise and when combined with a higher intensity the largest release is observed.

Influence of glucose and glycogen availability
With longer duration and higher intensity of exercise active human skeletal muscle will
inevitably achieve some degree of glycogen depletion. Ostrowski et al., (1998a) revealed that
while exercising at 75% VO2max, the highest concentrations of plasma IL-6 occurred at 2.5 hr, a
time point at which total glycogen depletion is imminent. Thus, appearance of IL-6 likely reflects
the energy status/fatigue level of skeletal muscle, i.e. glycogen availability. Data from Steensberg
et al. (2001) as well as Macdonald, et al. (2003) support this hypothesis, where larger release of
IL-6 from skeletal muscle occurred in a glycogen depleted state.
Muscle glycogen stores as well as exogenous glucose affect the magnitude of IL-6 release
from skeletal muscle during exercise. Many published findings report a blunting effect of IL-6
following ingestion of carbohydrates (CHO). In this regard, when fed CHO during 3 hours of
running, participants exhibit lower plasma IL-6 concentrations compared to their non-CHO fed
counterparts (Nieman, et al., 2003). A number of additional studies where endurance athletes
where fed CHO (6% in solution), also resulted in lowered circulating IL-6 (Nehlsen-Cannarella,
et al., 1997; Nieman, et al., 2001; Nieman, et al., 1998). However, Nieman et al. (2003) reported
no difference in plasma IL-6 concentrations between a CHO fed group and a control group
following 2 hr of heavy resistance training. However, the extent of circulating IL-6 did not reach
that of the previously mentioned studies, therefore endogenous CHO may only attenuate IL-6
release at a certain magnitude.
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Muscle glycogen content is a powerful stimulus for IL-6 release from muscle. While
performing one legged exercise (40% Wmax), Steensberg et al. (2001) observed that a significant
net release of IL-6 from a glycogen depleted leg (40% less, p < 0.05) occurred 1 hr before an
elevation in IL-6 was observed in a non-depleted exercised leg (4.38 ± 2.80 ng . min-1 vs. 0.36
± 0.14 ng . min-1, respectively). Moreover, following a randomized cross-over design (two week
washout), subjects cycled for one hour at 70% VO2peak where muscle biopsies were taken from
the vastus lateralis (opposite legs for respective trials). Higher IL-6 release was observed at each
10 min increment in glycogen depleted trials compared with high glycogen trails (p < 0.05)
(Macdonald et al., 2003).
Although IL-6 mRNA is influenced by glycogen availability, circulating IL-6 exhibits the
strongest associations. For example, muscle glycogen depletion (vastus lateralis, 35.3 ± 4.2%)
following treadmill running for 2.25 hr (70% VO2max) was inversely correlated with plasma IL6 concentrations (r= -0.72, p <0.001), yet it was not significantly associated with skeletal muscle
IL-6 mRNA post-exercise (r = -0.211, p = 0.321) (Nieman, et al., 2015). In a subsequent study
where subjects performed a 75 km cycling time trial (169 ± 26 min), depleted muscle glycogen
stores (vastus lateralis, 77.2% ± 17.4%) were once again significantly correlated with the changes
in plasma IL-6 (r = 0.462, p = 0.04) (Nieman, et al., 2016). Interesting to note, plasma IL-6
concentrations in both of these studies increased roughly 40-fold during similar durations and
intensity, yet muscle glycogen concentrations were substantially different within the biopsied
muscle. These puzzling results may be attributed to two mechanisms: 1) running recruits more
muscle mass resulting in a larger systemic release of IL-6 and 2) cycling isolates the vastus lateralis
more so than running, resulting in a larger glycogen depletion and subsequent IL-6 release. IL-6
levels in circulation are related to muscle glycogen content, however there are other elusive fatigue
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mechanisms/pathways that may influence IL-6 production. The effect of glucose and glycogen
availability on IL-6 production led to the understanding of IL-6 having a mediatory role in glucose
metabolism. In this regard, prolonged exercise results in IL-6 inhibition of glycogen synthase while
glycogen phosphorylase activity is promoted (Kanemaki, et al., 1998). Collectively, these findings
suggest that IL-6 in circulation during/following exercise is highly influenced by glycogen
depletion and glucose availability.

IL-6 as a metabolic regulator
Early evidence suggests that IL-6 may serve as a bioenergetic regulator, and exhibits roles
within substrate metabolism. In support, mice lacking IL-6 expression develop mature onset
obesity as well as elevated basal glucose levels in accordance with impaired glucose tolerance
(Wallenius, 2002). Furthermore, in humans, infusion of IL-6 induces intramuscular as well as
whole body lipolysis and fat oxidation (van Hall, et al., 2003; Wolsk, et al., 2010; Bruce et al.,
2004; Petersen, et al., 2005). When released in a fasted state, IL-6 mediates free fatty acid
mobilization (Wueest, et al., 2014). Although, IL-6 alters fat metabolism, other evidence points
towards a more central role within CHO metabolism during exercise. IL-6 clearly influences
glucose kinetics at rest and during exercise. In a dose dependent manner, infusion of recombinant
human IL-6 increased whole body glucose oxidation within human subjects (Stouthard et al.,
1995). Furthermore, Steensberg et al. (2001) concluded that a relationship exists between increased
glucose uptake and net IL-6 release during exercise at low intensities (40% Wmax). If correct, this
notion is consistent with subsequent observations which indicate a positive correlation exists
between IL-6 release and glucose uptake at 25% Wmax was observed (R = 0.82, p = 0.03) (Helge
et al. 2003). Accrued evidence demonstrates that IL-6 increases the delivery of glucose, glucose
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uptake, lipolysis and fatty acid oxidation via 5’-adenosine monophosphate-activated protein kinase
(AMPK).
AMPK is central to metabolic responses to exercise via stimulation of fatty acid oxidation,
glucose uptake and GLUT4 translocation (Ruderman, et al., 2006; Kahn, et al., 2005; Fisher, et
al., 2002). IL-6 directly affects AMPK activity within skeletal muscle and adipose tissue,
subsequently influencing substrate utilization (Kelley, et al., 2004; Carey, et al., 2006). Infusion
of IL-6 results in insulin stimulated whole body glucose uptake, increased glucose oxidation as
well as exercise induced whole body glucose production (Carey, et al., 2006; Febbraio, et al.,
2004). As little as 1 ng/ml of IL-6 elicits 2-fold increases GLUT4 translocation within skeletal
muscle (Carey et al., 2006). Additionally, GLUT4 content in inguinal white adipose tissue of IL6 KO mice reduced post-exercise, indicating that IL-6 contributes to the regulation of CHO
metabolism in adipose tissue in addition to skeletal muscle (Knudsen, et al., 2015; Knudsen, et al.,
2017). IL-6 appears to influence metabolic regulation and it is likely that IL-6 has an integral role
within glucose metabolism at rest, during and post-exercise. In addition to enhancing AMPK, IL6 also influences pyruvate dehydrogenase (PDH) activity (Bienso, et al., 2014; Gudiksen, et al.,
2016).
PDH is central in the regulation of substrate utilization, with higher activity leading
towards more CHO usage (Mourtzakis, e al., 2006). In mouse models (C57BL/6), injection of IL6 reduced pyruvate dehydrogenase (PDH) activity within skeletal muscle in a fed state but
increased PDH in a fasted state (Bienso, et al., 2014). These findings suggest that IL-6 exerts
physiologic influence on glucose metabolism differently when fed or fasted. As such, IL-6 release
appears to be part of complex concert of processes responsible for sensing whole body fuel
availability. Such as, IL-6 may assist in signaling the hypothalamus, like leptin, influencing whole
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body fuel balance (Wueest, et al., 2014). Concomitantly, IL-6 function is associated with altered
PDH activity during prolonged exercise. PDH activity is reported to be higher within IL-6 KO
mice, suggesting more CHO utilization. Gudiksen, et al., (2016) observed higher skeletal muscle
PDH levels within IL-6 skeletal muscle-specific KO mice at rest and at 60 min of exercise
compared to littermate floxed controls (p < 0.05). Additionally, in a sub study conducted by
Gudiksen and colleagues, mice lacking IL-6 ran for a shorter duration (> 10 min, p < 0.05) during
a graded exercise test to exhaustion. These findings suggest that IL-6 is in some way incorporated
in the overall regulation of CHO fuel usage at rest and during exercise, specifically sparing CHO
during prolonged exercise resulting in a longer durations. A role for IL-6 in CHO metabolism is
not exclusive to skeletal muscle, with evidence suggesting that IL-6 communicates with the liver
in an effort to regulate glucose availability. Bertholdt, et al. (2017) utilized skeletal muscle tissuespecific deletion of IL-6 to identify an influence on hepatic CHO metabolism. At rest, IL-6 KO
compared to wild type mice had higher PDH activity within the liver. Following 120 min of
exercise, hepatic glucose was significantly lower in IL-6 KO mice (p < 0.05). Taken together, these
data indicate that skeletal muscle IL-6 influences hepatic CHO oxidation at rest and hepatic
glucose release during exercise (Bertholdt, et al., 2017). All in all, research involving IL-6 and
metabolic regulation provide new insights into the orchestration of metabolic processes between
skeletal muscle and other tissues.
Emerging data suggests myokine functions of IL-6 may assist in regulating CHO
metabolism at rest as well as immediately following exercise. Influence on AMPK and PDH
highlights a role for IL-6 within substrate utilization. Evidence does not indicate that CHO
metabolism is dependent on IL-6, rather, IL-6 likely serves as a potentiator of the foundational
roles of CHO regulation. IL-6 has been observed to influence insulin activity and improve GLUT4
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transport post-exercise, hinting at a protective role in regards to glucose tolerance. Furthermore,
numerous studies applying knock-out models have reported adverse metabolic profiles within
rodents lacking skeletal muscle IL-6.

Protection against metabolic stress
Skeletal muscle derived IL-6 likely contributes to cytoprotection against metabolic stress
by improving glucose tolerance, enhancing insulin sensitivity and preventing pancreatic cell
damage. Although chronically elevated plasma IL-6 exist in low grade inflammatory states such
as obesity and type 2 diabetes IL-6 however is accompanied by TNF-α as well as IL-1β in these
states. Both TNF-α and IL-1β are detrimental to one’s metabolic profile. IL-1β is responsible for
pancreatic β-cell damage within type 2 diabetes and inhibiting IL-1β, pancreatic β-cell dysfunction
and glucose homeostasis is attenuated (Eguchi, et al., 2013; Ehses, et al., 2007). TNF-α is a prime
actor within peripheral insulin resistance (Hotamisligil, et al., 1996; Uysal, et al., 1997).
Specifically, TNF-α inhibits the phosphorylation of a vital substrate within the insulin signaling
cascade of GLUT4 translocation (Plomgaard, et al., 2005). Exercise induced IL-6 release inhibits
both of these detrimental cytokines upon infusion and exercise (Starkie, et al., 2003, Steensberg,
et al., 2003). In addition to blocking these damaging cytokines, IL-6 enhances insulin’s action
post-exercise and at rest.
Insulin sensitivity increases with repeated exercise bouts and is enhance immediately postexercise (King, et al., 1988; Wojtaszewski, et al., 2000). Carey et al (2006) specifically observed
that IL-6 infusion results in insulin stimulated glucose uptake. Furthermore, increased IL-6 levels
following exercise also stimulates glucagon-like peptide-1 (GLP-1) secretion from pancreatic βcells consequently improving insulin secretion (Ellingsgaard, et al., 2011). The influence of IL-6
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on insulin not only provides a mechanism to replenish energy stores post-exercise but it may serve
as protective mechanism against metabolic damage.
IL-6 prevents α-cell apoptosis as a result of metabolic stress, indicating protection against
successive metabolic stressors (Ellingsgaard, et al., 2008). Additionally, IL-6 is reported to
stimulate pancreatic α-cell proliferation and regulation (Ellingsgaard, et al., 2008). Impaired IL-6
signaling within hepatocytes leads to liver inflammation as well as insulin insensitivity
(Wunderlich, et al., 2010). Upon deletion of the membrane bound IL-6 receptor from hepatocytes,
glucose tolerance is reduced due to mitigated insulin-stimulated glucose transport within skeletal
muscle and fat (Wunderlich, et al., 2010). Although IL-6 appears to have beneficial outcomes on
metabolic homeostasis, over-expression of IL-6 exerts detrimental effects on liver and muscle
metabolic function due to hyperinsulinemia and decreased glucose uptake (Franckhauser, et al.,
2008). Using an electro-transfer in C57 mice, chronic overexpression of IL-6 resulted in a marked
inflammatory state within the liver with reported increases in serum amyloid A, TNF-α and SOCS3 (suppressor of cytokine signaling) gene expression (p < 0.05) (Franckhauser, et al., 2008). IL-6
overexpression also resulted in elevated levels of insulin within beta cells accompanied by reduced
glucose production from the liver. Furthermore, skeletal muscle metabolic function was
significantly altered as observed by reduced glucose uptake and GLUT-4 content as well as
decreases in mitochondrial genes: COX-2, ATP synthase and PGC1-α (p < 0.05) (Franckhauser,
et al., 2008). In addition, Kubaszek et al., (2003) identified a specific polymorphism within the
promoter region of the IL-6 gene in which individuals who possessed it had lower rates of wholebody glucose uptake and exhibited more resistance to insulin administration.
Together, these findings suggest further evidence that IL-6 is influential within CHO
metabolism. While overexpression of IL-6 appears to be detrimental, skeletal muscle derived IL-
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6 appears to have the ability to provide cytoprotection by battling TNF-α and IL-1β, enhancing
insulin and GLUT-4 action as well as promoting beneficial pancreatic function. In addition to
metabolic protection, IL-6 provides protection against ischemic bouts within the myocardium, as
seen by lessened necrotic tissue, and decreased markers of autophagy and apoptosis (McGinnis, et
al., 2015). Interestingly, the specific biological processes due to IL-6 are likely to be stimulusdependent in that exercise and ischemic preconditioning evoke different outcomes in terms of
indirect markers of autophagic and apoptotic involvement (McGinnis, et al., 2015; Smart, et al.,
2006; Dawn, et al., 2004; Matsushita, et al., 2005).

Future horizons
The ubiquitous nature of IL-6 is now well documented in a wealth of diverse research
findings from basic science to integrative physiology. Most recently, efforts have led to the
discovery of potential cytoprotective effects of skeletal muscle derived myokines. For instance,
IL-6 improves insulin action following exercise and likely protects against metabolic damage due
to its inhibitory effects on TNF-α and IL-1β. Aside from findings of IL-6 facilitating protection
from metabolic stress, recent evidence reveals potential cardioprotective properties. Different
genotypes of IL-6 exist, facilitation a new area of genetic and epigenetic research. With over
expression leading to disease states and the transient increases post-exercise exerting metabolic
benefits comes the question of whether or not certain individuals are at risk for disease due to more
or less expression of IL-6.

IL-6 Genotype Alterations
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Polymorphisms within cytokines are hypothesized to influence disease prevalence and
progression. Also, among the many exercise protocols reviewed, a majority reported large standard
deviations of plasma IL-6 concentrations within subjects, suggesting a responder versus nonresponder effect, a polymorphism may contribute to these observations (Nieman, et al., 2016). In
an effort to identify genetic predisposition to elevated IL-6 expression, Fishman et al., (1998)
identified a polymorphism in the 5’ flanking region of the IL-6 gene. The 5’ flanking region is
vital to the regulation of IL-6 gene expression. Researchers identified a single nucleotide alteration
from the G allele to C allele at position -174 (rs1800795). In vivo observations of Fishman and
colleagues indicated that the CC genotype resulted in lower IL-6 levels compared with the GC or
GG genotype. However, conflicting evidence exists in regards to the effects of these
polymorphisms. For instance, stimulation of monocytes with lipopolysaccharide resulted in higher
IL-6 production within GC and CC compared to GG genotypes (Patel, et al., 2010). The C allele
is associated with skeletal muscle damage following exercise and rhabdomyolysis (Funghetto, et
al., 2013; Yamin, et al., 2008). Specifically, Funghetto, et al., (2013) observed higher IL-6 activity
from zero to 48 hr post-eccentric exercise within CC and GC genotypes compared to GG.
Together, findings suggest that the C allele may promote more cytokine and subsequent
inflammatory actions. As mentioned earlier, Kubaszek et al., (2003) identified that subjects
expressing the CC genotype display insulin resistance and higher serum glucose concentration.
Individuals who expressed this CC genotype also exhibited lower energy expenditure along with
higher BMI compared with the G allele. In agreement, a lower walking distance during the six
minute walk test in elderly individuals was reported with individuals carry the C allele (p < 0.05)
(Nicklas, et al., 2005). Although these results indicate polymorphisms in IL-6 promoter cites play
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a role in IL-6 levels and ensuing effects, more research is needed to identify if these alterations in
genotypes factor into the myokine and cytoprotective properties of IL-6.

Cardioprotection
IL-6 provides cardioprotection due to a regulatory role in ischemic pre-conditioning
(McGinnis, et al., 2015; Smart, et al., 2006, Dawn, et al., 2004). An IL-6R gene single nucleotide
polymorphism has been linked to the predisposition of atrial fibrillation and elderly individuals
with GC genotype have been associated with higher levels of CVD and all-cause mortality (Lin et
al., 2014; Bruunsgaard, et al., 2004). IL-6 can be deleterious, however, it plays a distinct role in
the cardioprotective benefits of ischemic preconditioning (IPC). IPC is characterized as the process
of administering brief ischemic episodes which then increases the heart’s ability to withstand
ensuing ischemic reperfusion injury (I/R) (Dawn, et al., 2004). Dawn et al. (2004) identified that
IL-6 is necessary for beneficial IPC cardioprotection. Investigators identified IPC increases IL-6
expression within cardiomyocytes. Increased expression of IL-6 was reported to be responsible for
the activation of the JAK/STAT pathway and the succeeding increase in iNOS (inducible nitric
oxide synthase) and COX-2 (cyclooxygenase-2), both of which are mediators of IPC. In IL-6 KO
mice, researchers reported JAK/STAT suppression as well as abrogated expression of IPC
downstream mediators, iNOS and COX-2. Furthermore, Smart et al. (2006) observed that pretreatment of IL-6 (10ng/ml) 24 hr prior to ischemic reperfusion injury (I/R) increased iNOS
expression and induced a NO-dependent protective mechanism against reperfusion injury. More
interesting, upon blocking the PI-3K pathway, both iNOS and the apparent IL-6 dependent
protection were negated (Smart, et al., 2006). Data suggests that IL-6 acts through the canonical
pathways JAK/STAT and PI-3K in order to provide the cardioprotective benefits of IPC.
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Exercise prevents myocardial necrosis following I/R injury, although it is thought to
provide protection through different mechanisms than that of IPC. The aforementioned work by
McGinnis et al., (2015) served as groundwork in identifying inter-organ cross talk involving
myokines and the myocardium. Specifically, an exercise protocol was implemented in an effort to
identify if IL-6 produced from skeletal muscle signals the heart during the acute post-exercise
period. Knowing the influence of IL-6 on IPC, investigators hypothesized that skeletal muscle
derived/exercise induced IL-6 provides protection against I/R injury by signaling the heart. Upon
analysis of exercised and non-exercised myocardium, there were no differences in COX-2 and
iNOS between C57 wild type and IL-6 KO mice. Reports indicated that exercised wild type mice
were protected against I/R injury 24 hr post-exercise as observed by the larger infarct areas and
necrosis within exercised IL-6 KO mice (p = 0.049). Additionally, cleaved PARP (poly ADPribose polmerase), a marker of cellular apoptosis, was lower within ischemic and perfused tissues
of exercised wild-type mice compared to exercised IL-6 KO. Therefore, mice lacking IL-6
appeared to suffer increased apoptosis following I/R, which is in agreement with findings from
Matusushita, et al., (2005). Autophagy marker, cardiac Atg3, was also altered depending on the
presence of IL-6. For instance, ischemic as well as perfused tissue of exercised IL-6 KO mice had
higher cardiac Atg3 compared to the sedentary IL-6 KO counterparts, while exercise
C57 mice exhibited lower Atg3 levels when exercised. The difference in this autophagy marker
further suggests that without IL-6 present, exercise does not provide the same levels of protection
from I/R. Furthermore, despite the same COX-2 and iNOS expression within exercised and nonexercised mice, exercise protected against cardiac injury only in the mice that expressed IL-6. IL6 and its role in protection from I/R was believed to be dependent on COX-2 and iNOS action due
to the IPC models of Smart, et al. (2006) and Dawn et al. (2004). However, results from the
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McGinnis group shed light on the fact that IL-6 exerts protective effects during exercise
precondition through an alternate pathway than that of IPC. IL-6 was suggested to possibly act
through MAPK pathways due to the “protected” wild type exercised mice exhibiting larger p44/42
MAPK and p38 MAPK expression compared with exercised IL-6 KO mice. More specifically, the
increased MAPK levels were observed in both ischemic and perfused tissues, likely indicating that
I/R did not cause the increased signaling, instead exercise preconditioning was the suggested
source. Following exercise the Quindry group (McGinnis, et al., 2015) observed transient
increases of the membrane bound IL-6 receptor within the myocardium of wild type mice only,
indicating that this myokine has the ability to signal the heart in an endocrine fashion. Taking the
data from McGinnis et al. (2015), research should investigate the effects of IL-6 using tissue
specific KO models targeting myocardial IL-6 receptor in addition to skeletal muscle IL-6. These
exciting findings will propel future research into identifying additional cytoprotective capabilities
of this myokine. Skeletal muscle derived IL-6 serves as an architype for understanding skeletal
muscle’s endocrine capabilities, which will only continue to progress.

Conclusions
IL-6 exhibits alternate cellular actions when produced as a cytokine versus a myokine.
Cytokine processes are mostly involved in inflammatory responses, such as infection and tissue
damage following eccentric exercise. When produced directly from skeletal muscle, IL-6 acts in a
different manner than when produced from immune cells. Differences in IL-6 action are attributed
to IL-6 receptor signaling, location of production and subsequent upstream and downstream
secretory pathways, as well as the presence of pro-inflammatory cytokines (TNF-α and IL-1β).
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IL-6 is a myokine with the ability to deter pro-inflammatory cytokines, such as TNF-α and
IL-1β, providing a protective mechanism against disease progression. When in the presence of
TNF-α, IL-6 performs inflammatory processes. However, exercise induced increases in IL-6 are
not accompanied by TNF-α, rather IL-6 has the capability to inhibit pro-inflammatory cytokines
and stimulate anti-inflammatory molecules (Steensberg, et al., 2003). The anti-inflammatory
effects of exercise, as seen via IL-6, suggest an acute yet potent mechanism to fight progression of
low-grade inflammatory disease states, such as obesity and type 2 diabetes.
IL-6 release from skeletal muscle during exercise is strongly influenced by the energy
status of skeletal muscle. IL-6 elevations during endurance exercise are reduced when fed CHO
and increased when glycogen stores are diminished (Nehlsen-Cannarella et al., 1997; Nieman et
al. 1998; Nieman et al., 2001). In 2001, Starkie et al. published results indicating carbohydrate
ingestion mitigated plasma IL-6. As such these findings suggest that when the body is supplied
ample CHO, IL-6 is not produced significantly. Furthermore, exercising in a glycogen-depleted
state elevates plasma IL-6 (Steensberg et al., 2001, Helge, et al., 2003, Nieman, et al., 2015,
Nieman et al., 2016). From this evidence, there appears to be an interrelationship between IL-6
and the energy state of active skeletal muscle although, the precise mechanisms are not fully
understood. Collectively, a wealth of research has generated a developing hypothesis that IL-6
production following exercise is dependent on fatigue of skeletal muscle by exercise duration,
exercise intensity and ensuing glycogen depletion. Glycogen depletion is at the forefront due to
data indicating IL-6 having vital roles within CHO metabolism at rest and during exercise.
A mediatory role within substrate metabolism has been attributed to IL-6. IL-6 exerts its
effects on metabolic processes via its influence on AMPK and in turn PDH. Infusion of IL-6
initiates lipolysis and fat oxidation as well as glucose uptake. Action of IL-6 within metabolism
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seems to depend on being in a fed or fasted state. Fasting induced free fatty acid mobilization is
influenced by IL-6 activity (Wueest, et al., 2014). Meanwhile, IL-6 appears to play a more vital
role in CHO metabolism as seen by IL-6-dependent increases of insulin stimulated GLUT4
translocation and glucose uptake at rest and following exercise (Febbraio, et al., 2004; Carey et
al., 2006). The influence on insulin activity leads to speculation of IL-6 and energy restoration
processes post-exercise. In addition, IL-6 likely provides beneficial mechanisms at rest as well due
to its influence on insulin stimulated glucose uptake. Evidence also suggests a protective role for
IL-6 in metabolism due to proliferation and protective effects of pancreatic α-cells (Ellinsgaard, et
al., 2008).
In addition to inhibiting pancreatic α-cell apoptosis, IL-6 appears to be essential to the
cardioprotective effects of a short term exercise regimen. McGinnis, et al., (2015) observed that
the protection from ischemic reperfusion injury due to exercise preconditioning was dependent on
IL-6. More specifically, this team suggested that skeletal muscle derived IL-6 influenced signaling
within the heart in endocrine fashion protecting the myocardium from reperfusion injury.
Subsequent research will use findings from McGinnis et al., (2015) in order to identify specific
actions within the myocardium and other tissues in which IL-6 may induce protective mechanisms.
The dogma surrounding the relationship between inflammation and IL-6 has long vanished with
an abundance of research indicating anti-inflammatory effects, regulatory actions in metabolism
and cytoprotective properties.
The roles of IL-6 in health and disease are partially understood through compelling recent
evidence suggesting a valuable role of IL-6 (and exercise) in combating morbidity. Stated
differently, exercise is medicine and the IL-6 response to exercise is one of the many factors that
supports this notion. Exercise is a simple, yet effective treatment in mitigating inflammatory,
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metabolic and cardiac damage (Pedersen, et al., 2017; Quindry, 2017). Due to the far reaching
benefits of exercise participation, many individuals would benefit from protocols tailored toward
stimulating IL-6 release from skeletal muscle. Diabetes, heart disease and obesity are three of the
most prevalent disease states within the United States (PAGACR, 2008). Interleukin-6 has the
capabilities to combat all three of these diseases. IL-6 regulates CHO metabolism and assist in
glucose transport into skeletal muscle (Carey et al., 2006). Individuals suffering from diabetes
could greatly improve their metabolic profile through exercise and the IL-6 response that come
with it, due to the observed increase of insulin sensitivity and GLUT-4 translocation. Also, exercise
induced IL-6 suppresses TNF-α and IL-1β, which not are “inflammatory cornerstones” in many
disease states, including conditions provoked by obesity. By combating TNF-α and IL-1β,
interleukin-6 (and exercise) reduces inflammation within numerous diseases. Furthermore,
McGinnis, et al., (2015) reported exercised induced cardio protection 24 hr post-exercise, which
was dependent on IL-6. Other investigations report that IL-6 also protects against ischemic injuries
during IPC trials (Dawn et al., 2004; Smart et al., 2006). Skeletal muscle acts as an endocrine
organ with IL-6 being the most investigated effector myokine to date. Future investigations into
exercise myokines are needed to better understand the benefits of regular exercise. Next generation
experiments will likely result in the eventual application of myokine-related exercise therapy
prescriptions.
Personalization of an exercise plan is crucial to establish an effective stimulus for IL-6
release as well as ensure the safety of an individual. Due to a polymorphism within the promoter
region of the IL-6 gene which may predispose an individual to a more pronounced response than
others, the following guidelines are a general recommendation for any individual aiming to acquire
the benefits of exercise and subsequent IL-6 release. Training methods should target the known
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stimulus of IL-6 release; fatigue. High exercise intensity, long duration and low CHO availability
are all methods of achieving fatigue, with a combination of these factors resulting in the most
potent stimulus (Steensberg, et al., 2001; Ostrowski, et al., 1998; Leggate, et al., 2010; Nieman, et
al., 2015, 2016). Concentric modalities result in the largest plasma IL-6 concentrations, with
running eliciting the most prominent peaks during/post-exercise (Ostrowski, et al., 1998; Fischer,
et al., 2006). With a greater number working muscles the larger an IL-6 response will be, which
explains why running elicits some of the largest IL-6 concentrations in circulation (Nieman et al.,
1998, Starkie, et al., 2000, 2001, Ostrowski, 1998b). However, if running is not appropriate for an
individual, one could easily adapt and isolate a specific muscle group. Isolation exercise(s) are an
effective strategy due to an increased amount of glycogen depletion, as seen during cycling bouts
(Nieman et al., 2016). A more advanced training tool to elicit glycogen depletion and subsequent
IL-6 release would be two-a-days (Gollnick, Piehl & Saltin, 1974). For example, during the initial
bout an individual could target their glycogen stores (fast glycolytic energy system) by training at
a high intensity followed by an additional bout at a relatively high intensity once again in order to
achieve a quicker and more pronounced IL-6 release from muscle which were likely depleted of
glycogen in the initial bout. Thus, from the perspective of eliciting a rapid IL-6 spike post exercise,
one might limit CHO-replenishing practices. To this end, strategic CHO feeding should be
evaluation in ongoing research to better understand the influence on IL-6 myokine release
(Nehlsen-Cannarella, et al., 1997; Nieman, et al., 1998; Nieman, et al., 2001; Nieman, et al., 2003).
In regard to exercise intensity, evidence suggests that IL-6 release is more pronounced to type II
fibers. Thus, to the end of promoting IL-6 release, it now appears that exercise protocols that
consists of higher intensities due to type II fibers recruitment are most effective (Yamano, et al.,
2010; Hiscock, et al., 2004; McGinnis, et al., 2015). Therefore, models utilizing interval training
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serve as an effective strategy to evoke an exercise induced IL-6 response. Specifically, high
intensity interval training (HIIT) may be a beneficial option due to the increased demand of
glycolytic sources and ensuing glycogen depletion and fatigue (Knuiman, et al., 2015). New
investigations reported that HIIT elicits an IL-6 release, however responses are heavily influenced
by the number of intervals or total duration (Leggate, et al., 2010). The specific concentration of
IL-6 protein and therefore the amount of exercise needed for protective systemic effects remain
unknown and almost certainly varies among individuals. However, it is important to recall that the
cytoprotective benefits of an acute exercise bout are biochemical in nature and, as demonstrated
by McGinnis, et al., (2015), extend at least 9 days after their last exercise bout. More studies are
needed to identify how long these protective effects last in addition to clarifying the optimal
concentrations of circulating IL-6 and amount of exercise to induce metabolic and
cardioprotection. Aside from future investigations, engaged readers should advance this rationale
being cognizant of the fact that exercise is an accessible, cost effective and widely beneficial
strategy to combat various diseases; and that myokines such as IL-6 are just the “tip of the iceberg”
in promoting pleiotropic health benefits.
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